Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Ibexx who wrote (6416)	12/2/1998 10:18:00 PM
From: BigKNY3	Read Replies (2) \| Respond to of 9523

Merrill Lynch continues to pound the PFE table. Here are highlights from today's report on the FDA Advisory Meeting: -Overall, we felt the meeting was very positive. -The panel unanimously recommended that Celebrex be approved for use in OA and RA. -An important message from the meeting is that Celebrex 200mg taken once-daily was equally efficacious as the 100 mg twice-daily. Consequently, Celebrex can be dosed once-a-day in OA. -The pain indication is likely to be delayed until another clinical study demonstrates efficacy in acute pain. -We believe Celebrex will get a modified label from traditional NSAIDs that will underscore its GI safety benefit. This report and all ML research reports are available free at the following site. Merrill Lynch Reports (Only registration is required through 2/28/98) askmerrill.com Have PFun! BigKNY3